Brief: Biomed Lublin Updates Strategy

Synthaverse SA

02/11/2022 08:06

Nov 2 (Reuters) - Biomed Lublin Wytwornia Surowic i
Szczepionek SA  BML.WA :
    * UPDATES STRATEGY
    * BCG MEDICINAL PRODUCTS REMAIN COMPANY'S STRATEGIC PRIORITY
    * CURRENTLY THERE ARE BEING IMPLEMENTED TWO INVESTMENTS
RELATED TO
BCG MEDICINAL PRODUCTS - RESEARCH AND DEVELOPMENT CENTRE AND
ONKO BCG PRODUCTION FACILITY
    * RESULTS OF THESE PROJECTS SHOULD IMPACT COMPANY'S RESULTS
STARTING FROM 2025
    * MANAGEMENT RECOGNIZES POSSIBILITIES OF TAKING ACTIONS,
RESULTS
OF WHICH WILL BE VISIBLE IN PERIOD 2023-2025 IN FORM OF INCREASE
IN COMPANY'S REVENUES, IMPROVEMENT OF SALES STRUCTURE AND
PROFITABILITY
    * MANAGEMENT DECIDES TO START IMPLEMENTING PROJECTS AIMED AT
EXPANDING PRODUCT PORTFOLIO  AND DIVERSIFICATION OF SCOPE OF
SERVICES
    * DECIDES TO START COOPERATION WITH LEADERS OF
PHARMACEUTICAL
MARKET IN PROVISION OF SERVICES BY COMPANY IN FIELD OF
PRODUCTION AND PACKAGING OF MEDICINAL PRODUCTS, ESPECIALLY IN
FIELD OF PROBIOTICS
    * IN LONG-TERM PERSPECTIVE COMPANY INTENDS TO REBUILD ITS
OWN LINE
OF PROBIOTICS
    * STARTS MANUFACTURING PROCESS OF TWO MEDICINAL PRODUCTS
BIOHEMORIL AND BIOGLICEROL
    * PLANS TO CREATE ITS OWN SALES TEAM IN POLAND
    * PLANS TO FURTHER EXPAND MEDICINAL PRODUCT DISTREPTAZA TO
FOREIGN
MARKETS
    * IN CONNECTION WITH IMPLEMENTATION OF INDICATED STRATEGIC
DIRECTIONS, COMPANY IS CONSIDERING VARIOUS SOURCES OF FINANCING,
WHICH MAY INCLUDE DEBT OR EQUITY INSTRUMENTS
    * IN CONNECTION WITH ONGOING INVESTMENTS OF LONG-TERM
NATURE,
COMPANY IS CONSIDERING IMPROVING FINANCIAL STRUCTURE BY
REFINANCING EXISTING DEBT SOURCES WITH LONGER MATURITY DEBT
    * AT THE SAME TIME, MANAGEMENT WILL FOCUS ON LONG-TERM
ACTIVITIES,
I.E. THOSE WHOSE IMPACT WILL BE VISIBLE AFTER 2025
    * UNDER LONG-TERM ACTIVITIES IS CREATION OF NEW PRODUCT
PIPELINE

Source text for Eikon:  ID:nEM92ZFd1a 
Further company coverage:  BML.WA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))